Literature DB >> 28414143

The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders.

Kazuaki Taguchi1, Keishi Yamasaki2, Hiromi Sakai3, Toru Maruyama4, Masaki Otagiri5.   

Abstract

Bioactive gaseous molecules, such as oxygen (O2) and carbon monoxide (CO), are essential elements for most living organisms to maintain their homeostasis and biological activities. An accumulating body of evidence suggests that such molecules can be used in clinics as a medical gas in the treatment of various intractable disorders. Recent developments in hemoglobin-encapsulated liposomes, namely hemoglobin vesicles (HbV), possess great potential for retaining O2 and CO and could lead to strategies for the development of novel pharmacological agents as medical gas donors. HbV with either O2 or CO bound to it has been demonstrated to have therapeutic potential for treating certain intractable disorders and has the possibility to serve as diagnostic and augmenting product by virtue of unique physicochemical characteristics of HbV. The present review provides an overview of the present status of the use of O2- or CO-binding HbV in experimental animal models of intractable disorders and discusses prospective clinical applications of HbV as a medical gas donor.
Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biomimetics; controlled release; liposomes; nanotechnology; particle size

Mesh:

Substances:

Year:  2017        PMID: 28414143     DOI: 10.1016/j.xphs.2017.04.006

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Biomimetic carbon monoxide delivery based on hemoglobin vesicles ameliorates acute pancreatitis in mice via the regulation of macrophage and neutrophil activity.

Authors:  Kazuaki Taguchi; Saori Nagao; Hitoshi Maeda; Hiroki Yanagisawa; Hiromi Sakai; Keishi Yamasaki; Tomohiko Wakayama; Hiroshi Watanabe; Masaki Otagiri; Toru Maruyama
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

2.  Carbon monoxide releasing molecule-2 attenuates Pseudomonas aeruginosa-induced ROS-dependent ICAM-1 expression in human pulmonary alveolar epithelial cells.

Authors:  Chiang-Wen Lee; Cheng-Hsun Wu; Yao-Chang Chiang; Yuh-Lien Chen; Kuo-Ting Chang; Chu-Chun Chuang; I-Ta Lee
Journal:  Redox Biol       Date:  2018-07-04       Impact factor: 11.799

3.  Liposomal Artificial Red Blood Cell-Based Carbon Monoxide Donor Is a Potent Renoprotectant against Cisplatin-Induced Acute Kidney Injury.

Authors:  Kazuaki Taguchi; Yuto Suzuki; Moeko Tsutsuura; Kana Hiraoka; Yuki Watabe; Yuki Enoki; Masaki Otagiri; Hiromi Sakai; Kazuaki Matsumoto
Journal:  Pharmaceutics       Date:  2021-12-27       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.